Skip to main content
. Author manuscript; available in PMC: 2016 Apr 18.
Published in final edited form as: Leuk Lymphoma. 2015 Mar 11;56(10):2834–2840. doi: 10.3109/10428194.2015.1014368

Figure 2. Target inhibition by carfilzomib.

Figure 2

Chymotrypsin-like proteasome activity was measured in CLL cells from whole blood obtained at screening, pre-treatment, and post-treatment day 1, pre-treatment day 2, and pre and post-treatment day 8 using a commercial assay. Proteasome activity in each sample is shown relative to the activity in that patient's pretreatment sample.